Bleomycin sulfate from Streptomyces verticillus B8416-15UN

CAS Number:	9041-93-4
EC Number:	232-925-2
MDL number:	MFCD00070310
PubChem Substance ID:	24891950
NACRES:	NA.76

Bleomycin Sulfate is an antineoplastic antibiotic isolated from Streptomyces verticillus. It is recommended for use as a cell culture agent at 10-100 µg/mL.
Chemical structure: glycopeptide
Bleomycin is used in combination with Etoposide and Cisplatin to treat testicular, ovarian and cervical cancer. This combination is popular as BEP chemotherapy and has also been demonstrated as effective and most successful chemotherapy regimen in germ-cell tumors. Since it is a cytotoxic agent, bleomycin is known to induce endothelial damage the lung vasculature referred to as bleomycin-induced lung-injury or bleomycin-induced pneumonitis (BIP). Researchers have used this property of bleomycin to induce lung fibrosis in mouse and rat models.
15 units in serum bottle
Bleomycin sulfate binds to DNA, causes ssDNA scission at specific base sequences and inhibits DNA synthesis. This inhibitory action requires bleomycin to bind oxygen and a metal ion. It can also cleave RNA, to a lesser degree but more selectively. It acts as an inducer and regulator of apoptosis and inhibits tumor angiogenesis.
This product is a mixture of glycopeptides antibiotics containing Bleomycin A2 (70%) and B2(30%). Bleomycins differ from each other in the terminal amine and show varying biological activity.
This product should be stored at 2-8°C.
The product is soluble in water in water at 20 mg/mL and is active for several days. A solution of 2 units/mL in 0.1 M neutral potassium phosphate should be used within 14 days. A solution is active for three months at 3 units/mL in normal saline.
Keep container tightly closed in a dry and well-ventilated place, strongly hygroscopic

Quality Level	200,
product line	BioReagent
form	crystalline
specific activity	1.5-2.0 units/mg solid
application(s)	cell culture | mammalian: suitable
color	white
solubility	H2O: 20 mg/mL, clear, colorless
cation traces	Cu: 0.10%
Mode of action	DNA synthesis | interferes
antibiotic activity spectrum	fungi
storage temp.	2-8°C
SMILES string	[O-]S([O-])(=O)=O.C[C@@H](O)[C@@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2O[C@@H]3O[C@H](CO)[C@@H](O)[C@@H](OC(N)=O)[C@@H]3O)c4c[nH]cn4)C(=O)NCCc5nc(cs5)-c6ncc(s6)C(=O)NCCC[S+](C)C.C[C@@H](O)[C@@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@H](NC(=O)c7nc(nc(N)c7C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]8O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]8O[C@@H]9O[C@H](CO)[C@@H](O)[C@@H](OC(N)=O)[C@@H]9O)c%10c[nH]cn%10)C(=O)NCCc%11nc(cs%11)-c%12ncc(s%12)C(=O)NCCC[S+](C)C
InChI	1S/2C55H83N17O21S3.H2O4S/c2*1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-66-26)91-54-43(39(80)37(78)28(16-73)90-54)92-53-40(81)42(93-55(60)88)38(79)29(17-74)89-53)51(87)67-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-68-27(18-94-32)52-65-15-30(95-52)48(84)62-9-7-11-96(5)6;1-5(2,3)4/h2*14-15,18-19,21-25,28-29,34-43,53-54,64,73-75,77-81H,7-13,16-17,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,66,67,69,70,71,72,76,82,83,84,85,86,87,88);(H2,1,2,3,4)/t2*21-,22+,23+,24-,25-,28-,29+,34+,35+,36-,37+,38+,39-,40-,41-,42+,43-,53-,54-;/m00./s1
InChI key	OOXTWFJZZAJGKA-CNLAFNBISA-N

pictograms	GHS07,GHS08
signalword	Danger
hcodes	H302 + H312 + H332 - H315 - H317 - H319 - H334 - H335 - H351
pcodes	P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P308 + P313
Target Organs	Respiratory system
Personal Protective Equipment	Eyeshields,, Gloves,, type P1 (EN143) respirator filter,, type P3 (EN 143) respirator cartridges,
RIDADR	NONH for all modes of transport
WGK Germany	WGK 3